Texas A&M Innovation has recently issued the third round of funding for its Translational Investment Fund (TIF), a program that provides investments into the development of disclosed technologies toward commercially relevant ends. Faculty and staff inventors have the opportunity to secure investments of up to $75,000 to support year-long projects. To date, over $635,000 has been invested back into the development of promising Texas A&M University technologies for the market through this program.
The third funding cycle for the TIF program opened this past summer 2022, drawing in submissions from more than 17 different departments across campus. Following an extensive 2-part review and down selection process by a committee comprised of faculty advisors from across campus and Texas A&M Innovation staff, three project proposals deemed as most competitive and within scope of the program were selected for investment.
The first of the three investments this fall was awarded to support a project developing a novel treatment for epilepsy and traumatic brain injury (TBI), led by Dr. D. Samba Reddy from the Department of Neuroscience and Experimental Therapeutics in the School of Medicine.
A second investment was made to support a project investigating rho kinase inhibitors to treat microvascular diseases, led by Dr. Lih Kuo of the Department of Medical Physiology in the School of Medicine.
Lastly, a third investment was made to support a project to further develop a new compound to promote functional locomotor recovery after spinal cord injury led by Ph.D. candidate, Mr. Arthur Sefiani, of the Department of Neuroscience and Experimental Therapeutics in the School of Medicine.
Congratulations to these Round 3 Translational Investment Fund awardees; we look forward to seeing the successful advancements of these technologies in the future.
Learn more about the Translational Investment Fund program.
